Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • Alzheimer’s Disease
    • ALS
    • MSA
    • Parkinson’s Disease
    • Posters & Publications
  • News & Media
    • Press Releases
    • Events
    • In The News
    • Videos
    • Commentary
    • Podcasts
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Careers
  • Contact

In The News

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Oct 5, 2022

The ALS Curveball, Part II

Oct 5, 2022

The ALS Curveball, Part I

Aug 2, 2022

New Collaborative Research Grant will Support the Development of a Vaccine for Misfolded Protein Diseases

Jul 18, 2022

A Tale of Tangles We Weave, Chapter 4

Jul 14, 2022

ProMIS rings Nasdaq closing bell, July 13, 2022

Mar 17, 2022

A Tale Of Tangles We Weave

Jan 11, 2022

Stimulating the Next Generation of AD Treatment

Oct 5, 2021

Funding boost expands MND research in our region

Nov 4, 2020

Aducanumab edges closer to Potential Approval: Next up, the Advisory Committee meeting

Sep 23, 2020

Aducanumab: On the Regulatory Home Stretch in the USA

rss_feed RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy